Triple-Drug cocktail aims to stall aggressive breast cancer

NCT ID NCT04537286

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a combination of two chemotherapy drugs (nab-paclitaxel and cisplatin) plus an immunotherapy drug (camrelizumab) can help people with metastatic triple-negative breast cancer live longer without their disease getting worse. The study enrolls women aged 18 to 70 who have not received prior treatment for metastatic disease. Researchers are tracking how long the cancer stays under control and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of nab-paclitaxel, cisplatin, and camrelizumab
What this could lead to
If successful, this combination could become a new first-line treatment option for people with metastatic triple-negative breast cancer, potentially improving how long the disease is kept under control.
What could go wrong
This is a small, single-arm phase 2 study, so results may not be confirmed in larger trials. The three-drug combination may also cause more side effects than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.